Table 2.
Selected studies analyzing the effect of aPL on pregnancy morbidity in SLE patients
| Study (Year) | Study Design | n | aPL | PM in aPL + SLE | PM in aPL − SLE | Odds Ratio | 95% CI |
|---|---|---|---|---|---|---|---|
| Park et al. (2015) (57) | Retrospective | 50 | aCL | 53.8% | 34.7% | 2.2 | 0.6–7.6 |
| aβ2GPI | 16.7% | 9.1% | 2 | 0.1–39.1 | |||
| LA | 25% | 40.7% | 0.5 | 0.1–2.6 | |||
|
| |||||||
| Jakobsen et al. (2014) (58) | Retrospective | 39 | aCL, aβ2GPI, or LA | 43.5% | 13.1% | N/A | N/A |
|
| |||||||
| Buyon et al. (2015) (60) | Prospective | 385 | LA | 55.9% | 15.3% | 8.3 | 3.6–19.3 |
| aCL, aβ2GPI, or LA | 43.8% | 15.4% | 4.3 | 2.2–8.1 | |||
|
| |||||||
| Cortes Hernandes et al. (2002) (61) | Prospective | 60 | aCL | 72.5% | 41.8% | 3.7 | 1.5–8.8 |
| aβ2GPI | 84.8% | 38.7% | 8.9 | 3–26.1 | |||
| LA | 70% | 43.6% | 3 | 1.3–7.1 | |||
aCL: anticardiolipin antibodies; aβ2GPI: anti-β2-glycoprotein-I antibodies; CI: confidence interval; LA: lupus anticoagulant; N: number of patients; N/A: not applicable; PM: pregnancy morbidity; aPL: antiphospholipid antibodies; SLE: systemic lupus erythematosus